SynthesisAdvances in therapy2021
Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review.
Synthesis in Advances in therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Global health inequalities of chronic kidney disease: a meta-analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Pooled it
- Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials.Advances in therapy · 2022Pooled it
- Non-Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol-Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial.Nephrology (Carlton, Vic.) · 2025Trial
- Temporal trends in healthcare resource use and costs of chronic kidney disease in a Spanish population: the REDIC study.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Article
- Strategic rebalancing of kidney-related investments is key to implementing the WHO kidney health resolution.Nature reviews. Nephrology · 2025Article
- Association of kidney function impairment with healthcare service utilisation in individuals with type 2 diabetes: an observational follow-up study in primary care.BMC health services research · 2025Observational
- Economic Burden and Clinical Epidemiology of Dialysis: A Cross-Sectional Analysis of Chronic Kidney Disease Patients.Cureus · 2025Article
- Holistic Impact of CKD: A Clinical, Economic, and Environmental Analysis by IMPACT CKD.Kidney international reports · 2025Article
- Inside CKD: Cost-Effectiveness of Multinational Screening for CKD.Kidney international reports · 2025Article
- Healthcare costs in relation to kidney function among older people: the SCOPE study.European geriatric medicine · 2025Article
- Relationship between kidney function and healthy life expectancy: A historical cohort study.BMC nephrology · 2025Article
- Cost-effectiveness of treatment with finerenone in mild to advanced stage chronic kidney disease patients with type 2 diabetes from a societal perspective.BMJ public health · 2025Article
- Health-related quality of life and its predictors among chronic kidney disease patients: A hospital-based cross-sectional study.PloS one · 2025Article
- Optimising Access to Care for Patients with Heart and Kidney Diseases: A World Heart Federation and International Society of Nephrology White Paper.Global heart · 2025Review
- The Clinical and Economic Burden of Chronic Kidney Disease in Poland: Inside Patient-Level Microsimulation Modelling of CKD.Journal of clinical medicine · 2024Article
- Mendelian randomization analysis revealed that albuminuria is the key factor affecting socioeconomic status in CKD patients.Renal failure · 2024Article
- Association of peripheral eosinophil count with chronic kidney disease progression risk: a retrospective cohort study in Chinese population.Renal failure · 2024Observational
- Interactive exploration of adverse events and multimorbidity in CKD.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Observational
- Economic burden of recurrent hyperkalemia in patients with chronic kidney disease.Journal of managed care & specialty pharmacy · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe management of chronic kidney disease (CKD) costs in excess of $114 billion in the USA and £1.45 billion in the UK annually and is projected to increase alongside the increasing disease prevalence. The aim of this review was to evaluate the risks of cardiovascular (CV) morbidity, CV mortality or all-cause mortality based on KDIGO (Kidney Disease: Improving Global Outcomes) 2012 categorisations and estimate the additional costs and healthcare resource utilisation associated with CV morbidity linked to CKD severity in US and UK settings.
methodsA systematic literature review was conducted of studies reporting on the risk of CV morbidity, CV mortality or all-cause mortality characterised by CKD severity (published between January 2000 and September 2018). Additional costs and bed days associated with CKD severity in the USA and UK were estimated on the basis of median hazard ratios for CV morbidity risk at each CKD and albuminuria stage.
resultsTwenty-nine studies reported risk of adverse clinical outcomes based on KDIGO categorisations. Compared to stage 1 (or without) CKD, patients with stage 5 CKD and macroalbuminuria experienced a relative risk increase of 11.77-12.46 across all outcomes. Additional costs and bed days associated with stage 5 CKD and macroalbuminuria (versus stage 1 (or without) CKD) per 1000 patient years were US$3.93 million and 803 bed days and £435,000 and 1017 bed days, in the USA and UK, respectively.
conclusionRisks of adverse clinical outcomes increase with CKD and albuminuria severity and are associated with substantial additional costs and resource utilisation. Thus, early diagnosis and proactive management of CKD and its complications should be a priority for healthcare providers to alleviate the burden of CV morbidity and its management on healthcare resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.